2021
Early but not late convalescent plasma is associated with better survival in moderate-to-severe COVID-19
Briggs N, Gormally MV, Li F, Browning SL, Treggiari MM, Morrison A, Laurent-Rolle M, Deng Y, Hendrickson JE, Tormey CA, Desruisseaux MS. Early but not late convalescent plasma is associated with better survival in moderate-to-severe COVID-19. PLOS ONE 2021, 16: e0254453. PMID: 34320004, PMCID: PMC8318280, DOI: 10.1371/journal.pone.0254453.Peer-Reviewed Original ResearchConceptsCOVID-19 convalescent plasmaSevere COVID-19Convalescent plasmaPlasma recipientsHospital mortalityUnexposed cohortCCP administrationSevere COVID-19 infectionPropensity score-matched analysisCOVID-19Limited therapeutic optionsCOVID-19 infectionCoronavirus disease 2019CCP recipientsHospital stayPrimary endpointSecondary endpointsHospital daysHospital dischargeEarly administrationComplete followMechanical ventilationTherapeutic optionsClinical differencesSevere diseaseSARS-CoV-2 exacerbates proinflammatory responses in myeloid cells through C-type lectin receptors and Tweety family member 2
Lu Q, Liu J, Zhao S, Gomez Castro MF, Laurent-Rolle M, Dong J, Ran X, Damani-Yokota P, Tang H, Karakousi T, Son J, Kaczmarek ME, Zhang Z, Yeung ST, McCune BT, Chen RE, Tang F, Ren X, Chen X, Hsu JCC, Teplova M, Huang B, Deng H, Long Z, Mudianto T, Jin S, Lin P, Du J, Zang R, Su TT, Herrera A, Zhou M, Yan R, Cui J, Zhu J, Zhou Q, Wang T, Ma J, Koralov SB, Zhang Z, Aifantis I, Segal LN, Diamond MS, Khanna KM, Stapleford KA, Cresswell P, Liu Y, Ding S, Xie Q, Wang J. SARS-CoV-2 exacerbates proinflammatory responses in myeloid cells through C-type lectin receptors and Tweety family member 2. Immunity 2021, 54: 1304-1319.e9. PMID: 34048708, PMCID: PMC8106883, DOI: 10.1016/j.immuni.2021.05.006.Peer-Reviewed Original ResearchMeSH KeywordsAngiotensin-Converting Enzyme 2Binding SitesCell LineCOVID-19CytokinesGene Expression RegulationHost-Pathogen InteractionsHumansInflammation MediatorsLectins, C-TypeMembrane ProteinsModels, MolecularMyeloid CellsNeoplasm ProteinsProtein BindingProtein ConformationSARS-CoV-2Single-Domain AntibodiesSpike Glycoprotein, CoronavirusStructure-Activity RelationshipConceptsSARS-CoV-2Proinflammatory responseMyeloid cellsFamily member 2Robust proinflammatory responseC-type lectin receptorsCOVID-19 therapyCOVID-19 severityMember 2SARS-CoV-2 spikeCoronavirus disease 2019Single-cell RNA sequencing analysisReceptor-binding domainImmune hyperactivationImmune cellsDisease 2019Enzyme 2Pulmonary cellsC-type lectinRNA sequencing analysisCanonical receptorLectin receptorsPotential targetPredominant expressionReceptor interaction
2020
Prolonged incubation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in a patient on rituximab therapy
Koff A, Laurent-Rolle M, Hsu JC, Malinis M. Prolonged incubation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in a patient on rituximab therapy. Infection Control And Hospital Epidemiology 2020, 42: 1286-1288. PMID: 33023685, PMCID: PMC7578652, DOI: 10.1017/ice.2020.1239.Peer-Reviewed Case Reports and Technical NotesConceptsSevere acute respiratory syndrome coronavirus 2Acute respiratory syndrome coronavirus 2Respiratory syndrome coronavirus 2Syndrome coronavirus 2Coronavirus 2Coronavirus disease 2019Rituximab therapyPatient populationDisease 2019Longer quarantine durationQuarantine durationPatientsIncubation periodDaysHypogammaglobulinemiaTherapyProlonged incubation